Non-small cell lung cancer market is estimated to witness high growth, owing to increasing healthcare expenditure & significant drug pipeline
Global non-small cell lung cancer market is estimated to be valued at USD 26.10 Bn in 2024, exhibiting a CAGR of 9.4% over the forecast period 2024-2031. Advancements in targeted therapies and immunotherapy along with the development of combination treatments are providing new hope to patients. Furthermore, growing healthcare expenditure across major markets and increasing approval of novel drug therapies can drive the market growth.
Market Dynamics:
Increasing healthcare expenditure: Over the past few decades, healthcare spending has increased substantially across both developed and developing nations. Government initiatives aimed at enhancing accessibility of quality treatment along with rising disposable incomes have boosted healthcare spending. This has provided an impetus to investment in R&D of advanced treatment options for conditions like lung cancer.
Significant drug pipeline: Pharmaceutical companies are actively investing in developing novel drugs with improved efficacy and reduced side effects for non-small cell lung cancer. A burgeoning pipeline consisting of both small molecule drugs and biologics in clinical trials offer promising treatment options. Notable pipeline candidates include targeted therapies, immunotherapies, antibody drug conjugates that are anticipated to be commercialized in the near future.
Increased prevalence of lung cancer
Lung cancer is one of the most common cancers worldwide. According to the World Health Organization (WHO), lung cancer caused over 1.8 million new cases and 1.6 million deaths globally in 2020. Non-small cell lung cancer (NSCLC) accounts for around 80-85% of all lung cancer cases. The rising incidence of NSCLC due to factors such as smoking, air pollution and lifestyle changes can drive the non-small cell lung cancer market growth.
Advances in targeted drug therapies
Significant advancements have been made in understanding the molecular mechanisms of NSCLC and developing targeted drugs. Drugs targeting specific gene mutations or proteins crucial for tumor growth have shown improved efficacy and tolerability over conventional chemotherapy. With the approval of newer targeted drugs and combination therapies, treatment outcomes have improved. This has boosted demand and uptake of drugs like tyrosine kinase inhibitors like gefitinib, afatinib; ALK inhibitors like crizotinib, alectinib; anti-PD-1 drugs like nivolumab, pembrolizumab.
High treatment costs
Non-small cell lung cancer treatment often involves multiple lines of expensive targeted therapies, immunotherapy drugs and chemotherapies over the course of the disease. The high cost of newer targeted drugs, which may range between US$ 5,000 to US$ 10,000 per month, restricts their widespread adoption and poses affordability challenges in developing regions.
Patent expirations of key drugs
The patents of some major first-generation drugs like gefitinib (Iressa) and erlotinib (Tarceva) have expired, allowing the entry of low-cost generics. While increasing treatment access and affordability, generic competition has intensified pricing pressure on incumbent drug makers. A wave of patent expirations is expected over the next few years for other important drugs like crizotinib and afatinib, thus, hampering the non-small cell lung cancer market growth.
Emerging economies with large patient pools
Countries like China, India, Brazil and Russia account for a major share of the global disease burden but have lower diagnosis and treatment rates currently due to cost and awareness barriers. As living standards and access to healthcare improve in emerging nations, the incidence of NSCLC is projected increase. This vast untapped patient population offer significant opportunities for market players to expand access through innovative pricing models.
Combination therapies and pipeline drugs
While single-agent targeted therapies have improved outcomes, resistance limits their durability. Combining drugs with distinct mechanisms has emerged as a promising strategy to overcome resistance and improve survival. The non-small cell lung cancer pipeline boasts of many investigational combination regimens with immuno-oncology agents. Meanwhile, novel targets and drug classes like kinase inhibitors, antibody drug conjugates and vaccines also raise hopes for more efficacious and durable treatments.
Link: https://www.coherentmarketinsights.com/market-insight/non-small-cell-lung-cancer-market-241
Key Developments
- In January 2023, Novocure, an oncology company, announced positive results from the LUNAR study, which evaluated the safety and effectiveness of Tumor Treating Fields (TTFields) in combination with standard therapies for stage 4 non-small cell lung cancer (NSCLC) after progression on or following platinum-based therapy.
- In December 2022, the U.S. FDA granted approval to Krazati (adagrasib), a targeted therapy for adult patients with KRAS-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Krazati (adagrasib) was developed by Mirati, a commercial stage targeted oncology company.
- On March 6, 2022, Bristol Myers Squibb, a U.S.-based multinational pharmaceutical company, acquired Turning Point Therapeutics, a clinical-stage precision oncology company known for its internally developed investigational drugs targeting critical gaps in current cancer treatments. This acquisition expanded Bristol Myers Squibb's oncology portfolio with a leading late-stage precision oncology asset.
- On August 23, 2021, Pfizer, a U.S.-based multinational pharmaceutical and biotechnology corporation, completed its acquisition of Trillium Therapeutics Inc., a clinical-stage immuno-oncology company specializing in innovative cancer therapies. This acquisition enhanced Pfizer's leadership in oncology by integrating next-generation investigational immuno-therapeutics focused on hematological malignancies.
Key Players: F. Hoffmann-La Roche Ltd, Honeywell International Inc., AstraZeneca PLC, Merck & Co., Inc., Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Celgene Corporation, Amgen Inc., Johnson & Johnson, Gilead Sciences, Inc., AbbVie Inc., Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Sanofi, Teva Pharmaceutical Industries Ltd., Bayer AG
